Clinical trials
Observational Triple Negative Breast Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 2 |
| 2011 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 4 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 12 |
| Completed | 9 |
| Unknown status | 4 |
| Withdrawn | 3 |
| Suspended | 3 |
| Terminated | 3 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| A2 Biotherapeutics Inc. | 2 |
| Indiana University | 2 |
| M.D. Anderson Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| Texas Tech University Health Sciences Center, El Paso | 2 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Animated Dynamics, Inc. | 1 |
| Case Comprehensive Cancer Center | 1 |
| Cofactor Genomics, Inc. | 1 |
| Columbia University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 38 |
| Breast Neoplasms | 19 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Colorectal Neoplasms | 6 |
| Carcinoma, Renal Cell | 5 |
| Melanoma | 4 |
| Ovarian Neoplasms | 4 |
| Endometrial Neoplasms | 3 |
| Head and Neck Neoplasms | 3 |
| Kidney Neoplasms | 3 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.